Cited by 1,217Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 159 of the 161 references it cites were found in a registry or an index.

Alzheimer’s disease: Clinical trials and drug development

Mangialasche, Francesca, Solomon, Alina, Winblad, Bengt, Mecocci, Patrizia, Kivipelto, Miia·2010·The Lancet Neurology

DOI 10.1016/s1474-4422(10)70119-8

Open this paper in CoChat — free account

Abstract

Alzheimer's disease is the most common cause of dementia in elderly people. Research into Alzheimer's disease therapy has been at least partly successful in terms of developing symptomatic treatments, but has also had several failures in terms of developing disease-modifying therapies. These successes and failures have led to debate about the potential deficiencies in our understanding of the pathogenesis of Alzheimer's disease and potential pitfalls in diagnosis, choice of therapeutic targets, development of drug candidates, and design of clinical trials. Many clinical and experimental studies are ongoing, but we need to acknowledge that a single cure for Alzheimer's disease is unlikely to be found and that the approach to drug development for this disorder needs to be reconsidered. Preclinical research is constantly providing us with new information on pieces of the complex Alzheimer's disease puzzle, and an analysis of this information might reveal patterns of pharmacological interactions instead of single potential drug targets. Several promising randomised controlled trials are ongoing, and the increased collaboration between pharmaceutical companies, basic researchers, and clinical researchers has the potential to bring us closer to developing an optimum pharmaceutical approach for the treatment of Alzheimer's disease.

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(10)70119-8

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Alzheimer’s disease
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary Prevention: Systematic Review and Meta-analysis
Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560

Show all 161 references

Research works printed but not linked: 3

Solomon, 2010, A new target for Alzheimer's disease immunotherapy. 11th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2010, Geneva, Switzerland, Neurobiol Aging, 31, S29
Lenz R, Berry SM, Pritchett YL, et al. Novel investigation of a neuronal nicotinic receptor partial agonist in the treatment of Alzheimer's disease. 11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy; Geneva, Switzerland; March 24–27, 2010. P100.
Eriksdotter, 2010, Therapy of Alzheimer's disease with NGF. 11th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2010, Geneva, Switzerland, Neurobiol Aging, 31, S9

Sorted by citations

Items 201–300 of 1,000

TRPC6 specifically interacts with APP to inhibit its cleavage by γ-secretase and reduce Aβ production
Wang, J., Lu, R., Yang, J., Li, H., He, Z., Jing, N., Wang, X., & Wang, Y. (2015) · Nature Communications · doi:10.1038/ncomms9876 · Cited by 78
Advances in the therapy of Alzheimer’s disease: targeting amyloid beta and tau and perspectives for the future
Hampel, H. J., Schneider, L. S., Giacobini, E., Kivipelto, M., Sindi, S., Dubois, B., Broich, K., Nisticò, R., Aisen, P. S. S., & Lista, S. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.995637 · Cited by 82
Self-citation
Exendin-4 attenuates brain mitochondrial toxicity through PI3K/Akt-dependent pathway in amyloid beta (1–42)-induced cognitive deficit rats
Garabadu, D., & Verma, J. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.04.006 · Cited by 75
Neuroprotective effect of edible brown alga Eisenia bicyclis on amyloid beta peptide-induced toxicity in PC12 cells
Ahn, B. R., Moon, H. E., Kim, H. R., Jung, H. A., & Choi, J. S. (2012) · Archives of Pharmacal Research · doi:10.1007/s12272-012-1116-5 · Cited by 75
Vascular alterations in PDAPP mice after anti‐Aβ immunotherapy: Implications for amyloid‐related imaging abnormalities
Zago, W., Schroeter, S., Guido, T., Khan, K., Seubert, P., Yednock, T., Schenk, D., Gregg, K. M., Games, D., Bard, F., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.010 · Cited by 75
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: The case of chelerythrine
Brunhofer, G., Fallarero, A., Karlsson, D., Batista‐González, A., Shinde, P., Mohan, C. G., & Vuorela, P. M. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.09.040 · Cited by 75
Older patients are still under-represented in clinical trials of Alzheimer's disease
Banzi, R., Camaioni, P., Tettamanti, M., Bertele’, V., & Lucca, U. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0201-2 · Cited by 74
Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer’s disease: Current trends and future perspectives
La Barbera, L., Mauri, E., D’Amelio, M., & Gori, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.939855 · Cited by 74
Disease-modifying drugs in Alzheimer's disease
Scarpini, E. A., Galimberti, D., & Ghezzi, L. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s41431 · Cited by 74
A Common Pathogenic Mechanism Linking Type-2 Diabetes and Alzheimer's Disease: Evidence from Animal Models
Park, S. A. (2011) · Journal of Clinical Neurology · doi:10.3988/jcn.2011.7.1.10 · Cited by 74
Isorhamnetin enhanced cortico-hippocampal learning and memory capability in mice with scopolamine-induced amnesia: Role of antioxidant defense, cholinergic and BDNF signaling
Ishola, I. O., Osele, M. O., Chijioke, M. C., & Adeyemi, O. O. (2019) · Brain Research · doi:10.1016/j.brainres.2019.02.017 · Cited by 73
Modifying the progression of Alzheimer's and Parkinson's disease with deep brain stimulation.
Jakobs, M., Lee, D. J., & Lozano, A. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107860 · Cited by 68
EGb761 improves cognitive function and regulates inflammatory responses in the APP/PS1 mouse
Wan, W., Zhang, C., Danielsen, M., Li, Q., Chen, W., Chan, Y., & Li, Y. (2016) · Experimental Gerontology · doi:10.1016/j.exger.2016.05.007 · Cited by 73
Conjugates of tacrine and 1,2,4-thiadiazole derivatives as new potential multifunctional agents for Alzheimer’s disease treatment: Synthesis, quantum-chemical characterization, molecular docking, and biological evaluation
Махаева, Г. Ф., Ковалева, Н. В., Boltneva, N. P., Lushchekina, S. V., Рудакова, Е. В., Stupina, T. S., Terentiev, A. A., Serkov, I. V., Proshin, A. N., Radchenko, E. V., et al. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103387 · Cited by 72
Therapy for Alzheimer’s disease: Missing targets and functional markers?
Stoiljković, M., Horváth, T. L., & Hajós, M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101318 · Cited by 74
Donepezil attenuates Aβ-associated mitochondrial dysfunction and reduces mitochondrial Aβ accumulation in vivo and in vitro
Ye, C. Y., Lei, Y., Tang, X. C., & Zhang, H. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.02.020 · Cited by 72
Morin reverses neuropathological and cognitive impairments in APPswe/PS1dE9 mice by targeting multiple pathogenic mechanisms
Du, Y., Qu, J., Zhang, W., Bai, M., Zhou, Q., Zhang, Z., Li, Z., & Miao, J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.008 · Cited by 72
Using genetics to enable studies on the prevention of Alzheimer's disease
Crenshaw, D. G., Gottschalk, W. K., Lutz, M. W., Grossman, I., Saunders, A. M., Burke, J. R., Welsh-Bohmer, K. A., Brannan, S. K., Burns, D. K., & Roses, A. D. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.222 · Cited by 70
Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies
Zhao, J., Nussinov, R., & Ma, B. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.801514 · Cited by 71
Synthesis of 5-methyl-2,4-dihydro-3H-1,2,4-triazole-3-one’s aryl Schiff base derivatives and investigation of carbonic anhydrase and cholinesterase (AChE, BuChE) inhibitory properties
Özil, M., Balaydın, H. T., & Şentürk, M. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.02.045 · Cited by 69
Visual system manifestations of Alzheimer's disease
Kusne, Y. N., Wolf, A. B., Townley, K., Conway, M. D., & Peyman, G. A. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13319 · Cited by 74
Early diagnosis of Alzheimer's disease from elevated olfactory mucosal miR-206 level.
Moon, J., Lee, S.-T., Kong, I. G., Byun, J.-I., Sunwoo, J.-S., Shin, J.-W., Shim, J.-Y., Park, J.-H., Jeon, D., Jung, K.-H., et al. (2016) · Scientific Reports · doi:10.1038/srep20364 · Cited by 69
Phenserine Efficacy in Alzheimer's Disease
Winblad, B. G., Giacobini, E., Frölich, L., Friedhoff, L. T., Bruinsma, G., Becker, R. E., & Greig, N. H. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101311 · Cited by 69
Self-citation
The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid‐based therapies to improve on the poor current therapeutic outcomes
Fernández‐Ruíz, J. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14382 · Cited by 70
Royal Jelly Alleviates Cognitive Deficits and β-Amyloid Accumulation in APP/PS1 Mouse Model Via Activation of the cAMP/PKA/CREB/BDNF Pathway and Inhibition of Neuronal Apoptosis
You, M., Pan, Y., Liu, Y., Chen, Y., Wu, Y., Si, J., Wang, K., & Hu, F. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00428 · Cited by 70
Adenosine Receptors in Neuropsychiatric Disorders: Fine Regulators of Neurotransmission and Potential Therapeutic Targets
Pasquini, S., Contri, C., Merighi, S., Gessi, S., Borea, P. A., Varani, K., & Vincenzi, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031219 · Cited by 72
Novel 8-hydroxyquinoline derivatives targeting β-amyloid aggregation, metal chelation and oxidative stress against Alzheimer’s disease
Yang, X., Cai, P., Liu, Q., Wu, J., Yin, Y., Wang, X., & Kong, L. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.04.043 · Cited by 69
Genetic Variation in Targets of Antidiabetic Drugs and Alzheimer Disease Risk
Tang, B., Wang, Y., Jiang, X., Thambisetty, M., Ferrucci, L., Johnell, K., & Hägg, S. (2022) · Neurology · doi:10.1212/wnl.0000000000200771 · Cited by 68
Increased Susceptibility to Amyloid-β-Induced Neurotoxicity in Mice Lacking the Low-Density Lipoprotein Receptor
de Oliveira, J., Moreira, E. L. G., dos Santos, D. B., Piermartiri, T. C., Dutra, R. C., Pinton, S., Tasca, C. I., Farina, M., Prediger, R. D. S., & de Bem, A. F. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132228 · Cited by 62
Roles of Extracellular Chaperones in Amyloidosis
Wyatt, A. R., Yerbury, J. J., Dabbs, R. A., & Wilson, M. R. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.01.004 · Cited by 67
Novel conjugates of aminoadamantanes with carbazole derivatives as potential multitarget agents for AD treatment
Бачурин, С. О., Shevtsova, E. F., Махаева, Г. Ф., Grigoriev, V. V., Boltneva, N. P., Ковалева, Н. В., Lushchekina, S. V., Shevtsov, P. N., Неганова, М. Е., Redkozubova, O. M., et al. (2017) · Scientific Reports · doi:10.1038/srep45627 · Cited by 69
Amyloid and Alzheimer's Disease: Inside and Out
Tam, J. H. K., & Pasternak, S. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100013408 · Cited by 64
Insights into lncRNAs in Alzheimer’s disease mechanisms
Li, D., Zhang, J., Li, X., Chen, Y., Feng, Y., & Liu, Q. (2020) · RNA Biology · doi:10.1080/15476286.2020.1788848 · Cited by 68
Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential
de Matos, A. M., Macedo, M. P., & Rauter, A. P. (2017) · Medicinal Research Reviews · doi:10.1002/med.21440 · Cited by 68
An endothelial link between the benefits of physical exercise in dementia
Trigiani, L. J., & Hamel, É. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17714655 · Cited by 69
Hypometabolism, Alzheimer’s Disease, and Possible Therapeutic Targets: An Overview
Raut, S., Bhalerao, A., Powers, M., Gonzalez, M., Mancuso, S., & Cucullo, L. (2023) · Cells · doi:10.3390/cells12162019 · Cited by 65
Synergistic toxicity between tau and amyloid drives neuronal dysfunction and neurodegeneration in transgenic C. elegans
Benbow, S. J., Strovas, T. J., Darvas, M., Saxton, A. D., & Kraemer, B. C. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz319 · Cited by 64
A Bacteriophage Capsid Protein Provides a General Amyloid Interaction Motif (GAIM) That Binds and Remodels Misfolded Protein Assemblies
Krishnan, R., Tsubery, H., Proschitsky, M., Asp, E., Lulu, M., Gilead, S., Gartner, M., Waltho, J. P., Davis, P. J., Hounslow, A. M., et al. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.04.015 · Cited by 65
Characterization of New Specific Copper Chelators as Potential Drugs for the Treatment of Alzheimer’s Disease
Nguyen, M., Robert, A., Sournia‐Saquet, A., Vendier, L., & Meunier, B. (2014) · Chemistry - A European Journal · doi:10.1002/chem.201402143 · Cited by 67
Emerging roles of long non-coding RNAs in the pathogenesis of Alzheimer’s disease
Cortini, F., Roma, F., & Villa, C. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.01.001 · Cited by 65
Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice
Sivilia, S., Lorenzini, L., Giuliani, A., Gusciglio, M., Fernández, M., Baldassarro, V. A., Mangano, C., Ferraro, L., Pietrini, V., Baroc, M. F., et al. (2013) · BMC Neuroscience · doi:10.1186/1471-2202-14-44 · Cited by 65
Gold nanoparticle based dot-blot immunoassay for sensitively detecting Alzheimer's disease related β-amyloid peptide
Wang, C., Liu, D., & Wang, Z. (2012) · Chemical Communications · doi:10.1039/c2cc33568a · Cited by 64
C-Glycosylflavones Alleviate Tau Phosphorylation and Amyloid Neurotoxicity through GSK3β Inhibition
Liang, Z., Zhang, B., Su, W., Williams, P. G., & Li, Q. X. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00059 · Cited by 65
Cognitive-Enhancing Effects of a Polyphenols-Rich Extract from Fruits without Changes in Neuropathology in an Animal Model of Alzheimer’s Disease
Dal‐Pan, A., Dudonné, S., Bourassa, P., Bourdoulous, M., Tremblay, C., Desjardins, Y., & Calon, F. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160281 · Cited by 67
Bexarotene modulates retinoid-X-receptor expression and is protective against neurotoxic endoplasmic reticulum stress response and apoptotic pathway activation
Dheer, Y., Chitranshi, N., Gupta, V., Abbasi, M., Mirzaei, M., You, Y., Chung, R., Graham, S. L., & Gupta, V. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1041-9 · Cited by 63
APP accumulates with presynaptic proteins around amyloid plaques: A role for presynaptic mechanisms in Alzheimer's disease?
Jordà‐Siquier, T., Petrel, M., Kouskoff, V., Smailovic, U., Cordelières, F., Frykman, S., Müller, U., Mulle, C., & Barthet, G. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12546 · Cited by 63
Successes and Failures for Drugs in Late-Stage Development for Alzheimer’s Disease
Berk, C., & Sabbagh, M. N. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0108-6 · Cited by 63
Modulating 5-Ht 4 and 5-Ht 6 Receptors in Alzheimer’S Disease Treatment
Lalut, J., Karila, D., Dallemagne, P., & Rochais, C. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0031 · Cited by 65
The Implication of the Brain Insulin Receptor in Late Onset Alzheimer’s Disease Dementia
Folch, J., Ettcheto, M., Busquets, O., Sánchez‐López, E., Castro-Torres, R. D., Verdaguer, E., Manzine, P. R., Poor, S. R., García, M. L., Olloquequi, J., et al. (2018) · Pharmaceuticals · doi:10.3390/ph11010011 · Cited by 65
Striatal morphology in early-onset and late-onset Alzheimer's disease: a preliminary study
Pievani, M., Bocchetta, M., Boccardi, M., Cavedo, E., Bonetti, M., Thompson, P. M., & Frisoni, G. B. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.01.016 · Cited by 62
Neural tissue engineering using embryonic and induced pluripotent stem cells
Willerth, S. M. (2011) · Stem Cell Research & Therapy · doi:10.1186/scrt58 · Cited by 62
Imaging endpoints for clinical trials in Alzheimer’s disease
Cash, D. M., Rohrer, J. D., Ryan, N. S., Sebastien Ourselin, A., & Fox, N. C. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0087-9 · Cited by 62
The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer’s Disease Study
Gareri, P., Castagna, A., Cotroneo, A. M., Putignano, D., Conforti, R., Santamaria, F., Marino, S., & Putignano, S. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160808 · Cited by 62
Relationships among Cortical Glutathione Levels, Brain Amyloidosis, and Memory in Healthy Older Adults Investigated In Vivo with1H-MRS and Pittsburgh Compound-B PET
Chiang, G. C.-Y., Mao, X., Kang, G., Chang, E., Pandya, S., Vallabhajosula, S., Isaacson, R., Ravdin, L., Initiative, A. D. N., & Shungu, D. C. (2017) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5143 · Cited by 62
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Ritchie, C. W., Russ, T. C., Banerjee, S., Barber, B., Boaden, A., Fox, N. C., Holmes, C., Isaacs, J. D., Leroi, I., Lovestone, S., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0312-4 · Cited by 61
AF710B, an M1/sigma‐1 receptor agonist with long‐lasting disease‐modifying properties in a transgenic rat model of Alzheimer's disease
Hall, H., Iulita, M. F., Gubert, P., Aguilar, L. F., Ducatenzeiler, A., Fisher, A., & Cuello, A. C. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.11.009 · Cited by 65
Sleep–wake regulation and the hallmarks of the pathogenesis of Alzheimer’s disease
Egroo, M. V., Narbutas, J., Chylinski, D., González, P. V., Maquet, P., Salmon, É., Bastin, C., Collette, F., & Vandewalle, G. (2019) · SLEEP · doi:10.1093/sleep/zsz017 · Cited by 66
Functional and Phenotypic Diversity of Microglia: Implication for Microglia-Based Therapies for Alzheimer’s Disease
Xu, Y., Au, N. P. B., & Ma, C. H. E. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.896852 · Cited by 68
Dementia in older people: an update
LoGiudice, D., & Watson, R. (2014) · Internal Medicine Journal · doi:10.1111/imj.12572 · Cited by 63
Resonance light scattering as a powerful tool for sensitive detection of β-amyloid peptide by gold nanoparticle probes
Wang, C., Liu, D., & Wang, Z. (2011) · Chemical Communications · doi:10.1039/c1cc12939b · Cited by 61
Epigenetics: The neglected key to minimize learning and memory deficits in Down syndrome
Dekker, A. D., Deyn, P. P. D., & Rots, M. G. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.05.004 · Cited by 64
Triptolide treatment reduces Alzheimer’s disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD
Wang, Q., Xiao, B., Cui, S., Song, H., Qian, Y., Dong, L., An, H., Cui, Y., Zhang, W., He, Y., et al. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.018218 · Cited by 62
Paths to Alzheimer's disease prevention: From modifiable risk factors to biomarker enrichment strategies
Lista, S., Dubois, B., & Hampel, H. J. (2014) · The journal of nutrition health & aging · doi:10.1007/s12603-014-0515-3 · Cited by 61
Advances on Therapeutic Strategies for Alzheimer’s Disease: From Medicinal Plant to Nanotechnology
Hassan, N. A., Alshamari, A. K., Hassan, A. A., Elharrif, M. G., Alhajri, A. M., Sattam, M., & Khattab, R. R. (2022) · Molecules · doi:10.3390/molecules27154839 · Cited by 68
Blood Genome-Wide Transcriptional Profiles Reflect Broad Molecular Impairments and Strong Blood-Brain Links in Alzheimer's Disease
Naughton, B. J., Duncan, F. J., Murrey, D. A., Meadows, A. S., Newsom, D. E., Stoicea, N., White, P., Scharre, D. W., McCarty, D. M., & Fu, H. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140606 · Cited by 61
Alzheimer’s Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy
Khan, T. K., & Alkon, D. L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150238 · Cited by 62
Nodulisporiviridins A–H, Bioactive Viridins from Nodulisporium sp.
Zhao, Q., Chen, G., Feng, X., Yu, Y., He, R., Li, X., Huang, Y. Y., Zhou, W., Guo, L., Zheng, Y., et al. (2015) · Journal of Natural Products · doi:10.1021/np500912t · Cited by 61
Animal models of episodic memory
Crystal, J. D. (2018) · Comparative Cognition & Behavior Reviews · doi:10.3819/ccbr.2018.130012 · Cited by 59
After the grape rush: Sirtuins as epigenetic drug targets in neurodegenerative disorders
Huber, K., & Superti‐Furga, G. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.01.018 · Cited by 60
Bapineuzumab: Anti-β-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer‘s Disease
Panza, F., Frisardi, V., Imbimbo, B. P., D’Onofrio, G., Pietrarossa, G., Seripa, D., Pilotto, A., & Solfrizzi, V. (2010) · Immunotherapy · doi:10.2217/imt.10.80 · Cited by 59
Isobavachalcone and bavachinin from Psoraleae Fructus modulate Aβ42 aggregation process through different mechanisms in vitro
Chen, X., Yang, Y., & Zhang, Y. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.07.037 · Cited by 59
Revised NIA-AA criteria for the diagnosis of Alzheimer's disease: a step forward but not yet ready for widespread clinical use
Frisoni, G. B., Winblad, B. G., & O'Brien, J. T. (2011) · International Psychogeriatrics · doi:10.1017/s1041610211001220 · Cited by 61
Self-citation
New treatment strategies for Alzheimer's disease: is there a hope?
Aprahamian, I., Stella, F., & Forlenza, O. V. (2013) · Europe PMC (PubMed Central) · Cited by 59
SIRT1 as a therapeutic target for Alzheimer’s disease
Wong, S. Y., & Tang, B. L. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0023 · Cited by 59
Potential of GPCRs to modulate MAPK and mTOR pathways in Alzheimer’s disease
Franco, R., Martínez‐Pinilla, E., Navarro, G., & Zamarbide, M. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.01.004 · Cited by 61
Selective coactivation of α7- and α4β2-nicotinic acetylcholine receptors reverses beta-amyloid–induced synaptic dysfunction
Roberts, J. P., Stokoe, S. A., Sathler, M. F., Nichols, R. A., & Kim, S. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100402 · Cited by 64
Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative
Grill, J. D., Di, L., Lu, P. H., Lee, C., Ringman, J., Apostolova, L. G., Chow, N., Kohannim, O., Cummings, J. L., Thompson, P. M., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.03.006 · Cited by 58
Screening novel drug candidates for Alzheimer’s disease by an integrated network and transcriptome analysis
Peng, Y., Yuan, M., Xin, J., Liu, X., & Wang, J. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa563 · Cited by 59
Alzheimer’s-Related Peptide Amyloid-β Plays a Conserved Role in Angiogenesis
Cameron, D. J., Galvin, C. J., Alkam, T., Sidhu, H., Ellison, J., Luna, S., & Ethell, D. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039598 · Cited by 59
Latest treatment options for Alzheimer’s disease, Parkinson’s disease dementia and dementia with Lewy bodies
Broadstock, M., Ballard, C. G., & Corbett, A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.936848 · Cited by 68
Antibody-based therapy in Alzheimer's disease
Pul, R., Dodel, R. C., & Stangel, M. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.552884 · Cited by 59
Curcumin improves tau-induced neuronal dysfunction of nematodes
Miyasaka, T., Xie, C., Yoshimura, S., Shinzaki, Y., Yoshina, S., Kage‐Nakadai, E., Mitani, S., & Ihara, Y. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.11.004 · Cited by 59
Hematoxylin Inhibits Amyloid β-Protein Fibrillation and Alleviates Amyloid-Induced Cytotoxicity
Tu, Y., Ma, S., Liu, F., Sun, Y. P., & Dong, X. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6b06878 · Cited by 58
9-Substituted acridine derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors possessing antioxidant activity for Alzheimer's disease treatment
Махаева, Г. Ф., Lushchekina, S. V., Boltneva, N. P., Serebryakova, O. G., Рудакова, Е. В., Ustyugov, A. A., Бачурин, С. О., Shchepochkin, A. V., Чупахин, О. Н., Чарушин, В. Н., et al. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.09.028 · Cited by 58
Evaluation of neuroprotective and anti-amnesic effects of Elaeagnus umbellata Thunb. On scopolamine-induced memory impairment in mice
Nazir, N., Zahoor, M., Nisar, M., Karim, N., Latif, A., Ahmad, S., & Uddin, Z. (2020) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-020-02942-3 · Cited by 57
Rhein Ameliorates Cognitive Impairment in an APP/PS1 Transgenic Mouse Model of Alzheimer’s Disease by Relieving Oxidative Stress through Activating the SIRT1/PGC‐1α Pathway
Yin, Z., Gao, D., Du, K., Chen, H., Liu, Y., Wang, Y., & Gao, X. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/2524832 · Cited by 58
Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development
Nordberg, A. K. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt96 · Cited by 58
Metabolomics: a novel approach to identify potential diagnostic biomarkers and pathogenesis in Alzheimer’s disease
Xu, X., Huang, Y. M., Wang, G., & Chen, S. (2012) · Neuroscience Bulletin · doi:10.1007/s12264-012-1272-0 · Cited by 57
A Novel, Multi-Target Natural Drug Candidate, Matrine, Improves Cognitive Deficits in Alzheimer’s Disease Transgenic Mice by Inhibiting Aβ Aggregation and Blocking the RAGE/Aβ Axis
Cui, L., Cai, Y., Cheng, W., Liu, G., Zhao, J., Cao, H., Tao, H., Wang, Y., Yin, M., Liu, T., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9783-8 · Cited by 58
Ferulic Acid Ameliorates Alzheimer's Disease-like Pathology and Repairs Cognitive Decline by Preventing Capillary Hypofunction in APP/PS1 Mice
Wang, N.-Y., Li, J., Liu, W., Huang, Q., Li, W., Tan, Y., Liu, F., Song, Z., Wang, M.-Y., Xie, N., et al. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01024-7 · Cited by 59
A modified formulation of Chinese traditional medicine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease
Jeon, S., Bose, S., Hur, J., Jun, K.-Y., Kim, Y., Cho, K. S., & Koo, B. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.06.046 · Cited by 57
Inflamma-MicroRNAs in Alzheimer’s Disease: From Disease Pathogenesis to Therapeutic Potentials
Liang, Y., & Wang, L. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.785433 · Cited by 56
In Vivo Screening of Traditional Medicinal Plants for Neuroprotective Activity against Aβ42 Cytotoxicity by Using Drosophila Models of Alzheimer’s Disease
Liu, Q. F., Lee, J. H., Kim, Y., Lee, S., Hong, Y. K., Hwang, S., Oh, Y., Lee, K., Yun, H. S., Lee, I., et al. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00459 · Cited by 58
Trans ε-viniferin is an amyloid-β disaggregating and anti-inflammatory drug in a mouse primary cellular model of Alzheimer's disease
Vion, E., Page, G., Bourdeaud, E., Paccalin, M., Guillard, J., & Bilan, A. R. (2017) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2017.12.003 · Cited by 56
Effects and mechanisms of natural products on Alzheimer’s disease
Yang, Z., Zhou, D.-D., Huang, S., Fang, A., Li, H., & Zhu, H. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1985428 · Cited by 59
Neuroprotective effect of SuHeXiang Wan in Drosophila models of Alzheimer's disease
Hong, Y. K., Park, S. H., Lee, S., Hwang, S., Lee, M. J., Kim, D., Lee, J. H., Han, S. Y., Kim, S. T., Kim, Y., et al. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.02.012 · Cited by 55
Epidemiology, Assessment, and Treatment of Dementia
Nowrangi, M. A., Rao, V., & Lyketsos, C. G. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.02.004 · Cited by 58
Increased Levels of Antigen-Bound β-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer’s Disease Patients
Maftei, M., Thurm, F., Schnack, C., Tumani, H., Otto, M., Elbert, T. R., Kolassa, I., Przybylski, M., Manea, M., & Arnim, C. A. F. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068996 · Cited by 54
The biomarker-based diagnosis of Alzheimer's disease. 2—lessons from oncology
Boccardi, M., Gallo, V., Yasui, Y., Vineis, P., Padovani, A., Mosimann, U. P., Giannakopoulos, P., Gold, G., Dubois, B., Jack, C. R., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.01.021 · Cited by 56
Self-citation
Current status of renin–aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease
Ashby, E. L., & Kehoe, P. G. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.812631 · Cited by 55

Authors: Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M.
Affiliations: University of Perugia (IT)
University of Eastern Finland (FI)
Karolinska Institutet (SE)
Corresponding author: Winblad, Bengt
ORCID: Mangialasche, Francesca
Solomon, Alina
Winblad, Bengt
Mecocci, Patrizia
Kivipelto, Miia
Venue: The Lancet Neurology
Publisher: Elsevier BV
Published: 2010-07
Volume: 9
Issue: 7
Pages: 702-716
ISSN: 1474-4422 (ISSN-L)
DOI: 10.1016/s1474-4422(10)70119-8
OpenAlex: W2129267808
Cited by: 1,217
References: 161
Citations by year: 2026: 31 · 2025: 47 · 2024: 53 · 2023: 45 · 2022: 91 · 2021: 80 · 2020: 69 · 2019: 77 · 2018: 82 · 2017: 79 · 2016: 78 · 2015: 89 · 2014: 121 · 2013: 97 · 2012: 80
FWCI: 8.96
Type: journal article
Language: en
Update notices: erratum (2011-06-01)
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords: Alzheimer's disease, drug development, clinical trials, disease-modifying therapy, symptomatic treatment, therapeutic target, pathogenesis, dementia, drug interactions, randomized controlled trials, translational research
MeSH terms: Alzheimer Disease, Clinical Trials as Topic, Humans, Antipsychotic Agents, Drug Design

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Alzheimer’s disease: Clinical trials and drug development

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks